Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02773446 · ClinicalTrials.gov registry record · NA
Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A
A NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- NA
- Development phase
- 47
- Enrollment target
NCT02773446: Completed NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT02773446 is a NA study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 47 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02773446, a NA study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 47 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safe and optimal dose and regimen (fasting duration) for administering the challenge ETEC strain B7A, a CS6 expressing ETEC strain. Additionally, an assessment of homologous protection following rechallenge with B7A will be assessed.
Primary Outcome
Solicited symptoms (vomiting, abdominal pain, bloating, lightheadedness, anorexia, generalized myalgia, arthralgias, abdominal cramping, constipation, nausea, malaise, headache, flatulence)
Interventions
- BIOLOGICAL ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-04 |
| Est. Completion | 2016-12 |
| Phase | NA |
What the finished NCT02773446 record still lists
NCT02773446 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer is the first listed.
NCT02773446 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02773446 about?
NCT02773446 is a clinical study titled "Human Challenge Model Refinement With Enterotoxigenic Escherichia Coli Strain B7A". The purpose of this study is to determine the safe and optimal dose and regimen (fasting duration) for administering the challenge ETEC strain B7A, a CS6 expressing ETEC strain. Additionally, an assessment of homologous protection following rechallenge with B7A will be assessed.
What is the current status of trial NCT02773446?
This trial is currently completed. It is a NA study. The enrollment target is 47 participants. The study started on 2016-04. Estimated completion is 2016-12.
What interventions are being tested in trial NCT02773446?
The interventions under investigation include: ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer (BIOLOGICAL).
Who is sponsoring clinical trial NCT02773446?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02773446's enrollment target sits among peer trials
47 1400th of 2000 higher than 599 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia